NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
Clinical Trials
12 trialsNCT02362035 2025-12-11
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT04402138 2025-05-13
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03623373 2025-05-04
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT02112526 2024-12-20
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 1 Completed
NCT04930536 2024-11-22
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
AstraZeneca
Phase 4 Completed
NCT03788291 2024-09-26
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
University of Rochester
Phase 2 Completed
NCT02211014 2020-07-31
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
Acerta Pharma BV
Phase 1 Completed
NCT02362048 2019-10-01
KEYNOTE144
Acerta Pharma BV
Phase 2 Completed
NCT02537444 2019-09-25
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
Acerta Pharma BV
Phase 2 Completed
NCT02448303 2019-09-12
KEYNOTE166
Acerta Pharma BV
Phase 2 Completed
NCT02454179 2019-09-12
KEYNOTE147
Acerta Pharma BV
Phase 2 Completed